Why The Pearson LSE:PSON Story Is Shifting As Targets Tighten Around Mid Single Digit Growth

What the latest Pearson price target tweak really signals Pearson’s base case fair value has been nudged from £12.51 to ...

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...